// App-Quantinova.ai

1626 : Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Researchers

Presenter

  • Anne W Beaven

Principal Investigators

  • Jon P. Gockerman

  • Louis F. Diehl

  • Cristina Gasparetto

  • Thomas C. Shea

  • Carlos de Castro

  • Joseph O. Moore

  • David A. Rizzieri

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Hematological malignancies

  • Thrombocytopenia

  • B cell lymphomas

  • Constipation

  • Hypertension

  • Albuminuria

  • Lymphomas

  • Anemia

  • Sepsis

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Vatalanib

  • L-Tyrosine

  • ZK-222584

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved